

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement..*



開拓藥業有限公司\*

**KINTOR PHARMACEUTICAL LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9939)**

**APPOINTMENT OF JOINT COMPANY SECRETARY  
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND  
8.17 OF THE LISTING RULES  
AND  
CHANGE OF PROCESS AGENT**

**APPOINTMENT OF JOINT COMPANY SECRETARY**

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Mr. Ming Ming CHEUNG (“**Mr. Cheung**”) has been appointed as a joint company secretary with effect from 12 May 2023.

The biographical details of Mr. Cheung and Mr. Wai Chiu WONG (“**Mr. Wong**”), the other joint company secretary of the Company, are set out as follows:

Mr. Cheung, aged 46, joined the Group in September 2021. He was the vice president of investment and overseas business of the Group until April 2023, and was appointed as the chief financial officer (“**CFO**”) of the Company with effect from 14 April 2023. Mr. Cheung has over 15 years’ of work experience in the capital market. Prior to joining the Group, he was Head of Leveraged & Acquisition Finance of Haitong International Securities Group Limited, a company listed on the Stock Exchange (stock code: 0665). He was in charge of leveraged acquisition finance and equity fund investments respectively. Mr. Cheung also worked in ING Bank Hong Kong Branch for over 5 years. He was responsible for corporate client coverage and merger and acquisition financial advisory. Mr. Cheung obtained his bachelor’s degree in Biochemistry from the Hong Kong University of Science and Technology in 1999 and Master of Philosophy in Bioinformatics from Medical School, the University of Hong Kong in 2002.

Mr. Wong is the Associate Director of SWCS Corporate Services Group (Hong Kong) Limited. Mr. Wong has extensive experience in compliance and listed companies secretarial work. Mr. Wong is a fellow of Hong Kong Chartered Governance Institute (previously known as Hong Kong Institute of Chartered Secretaries), a fellow of the Chartered Governance Institute, a member of CPA Australia, a member of the Hong Kong Trustee Association and a Certified Trust Practitioner. Mr. Wong possesses a B. Soc. Sc. (Hon.) from the University of Hong Kong, a Post-Graduate diploma in Hong Kong and United Kingdom law from the Manchester Metropolitan University in the United Kingdom, Master degree in Corporate Governance from the Hong Kong Polytechnic University, Master Degree in Arbitration and Dispute Resolution from City University of Hong Kong and Master of Applied Science Degree from the University of Technology, Sydney, Australia.

**WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE RULES (THE “LISTING RULES”) GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)**

The Company has applied to the Stock Exchange and has already been granted with a waiver (“**Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the three-year period from 12 May 2023 to 11 May 2026 (“**Waiver Period**”) in relation to the eligibility of Mr. Cheung to act as a joint company secretary. Mr. Cheung would be assisted by Mr. Wong, the other joint company secretary, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. The conditions of the Waiver include:

- i. Mr. Cheung will be assisted by Mr. Wong during the Waiver Period; and
- ii. the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. Cheung, having had the benefit of Mr. Wong’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Company is of the view that while it is important for company secretary to possess the acceptable qualification or relevant experience under Rule 3.28 of the Listing Rules, it is also vital for the company secretary to have experience relevant to the Group's industry and operations, and close working relationship with the management, the Board and shareholders in order to perform the function of a company secretary and to take the necessary actions in the most effective manner. While Mr. Cheung currently does not possess the acceptable qualification or sufficient experience under Rules 3.28 of the Listing Rules, Mr. Cheung, being the existing CFO of the Company, is primarily responsible for the investor relations and public relations management of the Group and plays a main role in information disclosure, and he has substantial familiarity with the day-to-day operations of the Group. Mr. Cheung and his investor relations team have been actively involved in communications with the Board and shareholders, organising Board and shareholders' meetings and is the key contact person of the Board and shareholders. In light of the foregoing, Mr. Cheung has accumulated extensive experience in handling company secretarial matters. As such, the Board considers it the most efficient to maintain joint company secretary arrangement so that Mr. Cheung will be assisted by Mr. Wong to attain the relevant experience during the Waiver Period and become capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

## **CHANGE OF PROCESS AGENT**

The Board further announces that Mr. Cheung was appointed as the authorized representative of the Company for the service of process or notices on behalf of the Company in Hong Kong under the Companies Ordinance (Chapter 622 of the laws of Hong Kong) ("**Process Agent**") in place of Ms. Yan LU with effect from 13 April 2023.

The Board would like to take this opportunity to welcome Mr. Cheung on his new appointments.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**  
**Dr. Youzhi Tong**  
*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, 12 May 2023

*As of the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

\* *For identification purpose only*